Commercialization
-
Deep Dive
What if a CRISPR cure isn’t such an easy choice?
A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.
By Ned Pagliarulo , Shaun Lucas • Nov. 9, 2023 -
What’s next for COVID dark horse Novavax?
Novavax scored a new COVID vaccine go-ahead for the 2023-24 season, but is it the boost the company needs?
By Kelly Bilodeau • Oct. 30, 2023 -
Q&A // Red Jacket winners 2023
Red Jacket: Adele Gulfo, a commercialization guru
With a knack for melding science and patient-focused marketing techniques, the CEO of the biopharma commercial unit at Sumitomo Pharma America has notched blockbuster successes throughout her career.
By Karissa Waddick • Oct. 27, 2023 -
3 marketing tips for biotechs emerging from stealth
In a crowded biotech market, here’s how your company can stand out to investors.
By Karissa Waddick • Oct. 6, 2023 -
PharmaVoice 100
PharmaVoice 100s: Brand and commercialization pros
Leaders decoding the complex language of drug development to push treatments past the finish line and into patients’ hands.
By Karissa Waddick • Oct. 4, 2023 -
How pharma marketers can reclaim the drug pricing narrative
As Medicare negotiations heat up, it’s more important than ever for pharma companies to communicate their value. Here’s how.
By Karissa Waddick • Sept. 28, 2023 -
Sponsored by Phil Inc
Optimizing your hub services program with a gross-to-net lens
In today’s Biopharma landscape, considering Gross-to-Net is essential for effectively designing and optimizing patient support programs.
Sept. 25, 2023 -
Q&A
As the opioid crisis seethes, a long-lasting treatment could offer new ammunition
Launched this month, Brixadi from Braeburn gives patients a new tool to overcome addiction.
By Michael Gibney • Sept. 21, 2023 -
Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’
Forecasts from the biggest pharma companies follow a pattern of thinking big and manifesting the desired outcome.
By Michael Gibney • Sept. 15, 2023 -
O.G. Ice-T teams up with Sanofi in horror-themed flu vax ad
The French pharma’s latest vaccine campaign aims to raise awareness about the flu’s complications for marginalized groups.
By Karissa Waddick • Sept. 14, 2023 -
Q&A
In the renal space, innovation could tackle health disparities. But the system doesn’t reward it.
Reimbursement challenges have created barriers for new dialysis products, according to the chief commercial officer of CorMedix.
By Michael Gibney • Sept. 14, 2023 -
Finding the right flu vaccine is hard. Getting people to take it is harder.
Experts have determined the strains of this year’s flu season — now the question is whether people are too fatigued by the pandemic to be immunized.
By Michael Gibney • Aug. 30, 2023 -
Are weight loss drugs a win for the global economy?
As Novo Nordisk’s drug Wegovy sways Denmark’s economy, we're examining wider implications for the weight loss market.
By Karissa Waddick • Aug. 28, 2023 -
Henrietta Lacks’ immortal cells put biopharma profits under a microscope
The HeLa cell line’s contributions to medical science were obtained without permission, and now biotechs profiting from its use are answering for it.
By Michael Gibney • Aug. 23, 2023 -
Behind Flagship Pioneering’s triumphs and tribulations
From the rise of Moderna to the fall of Kaleido, here's a look at the VC fund's biggest successes and failures to date.
By Karissa Waddick • Aug. 18, 2023 -
Demand for weight loss drugs soars to nearly half of Americans
Drugs like the buzzy Ozempic are high on consumers’ radar — but lofty barriers to access remain.
By Alexandra Pecci • Aug. 15, 2023 -
Podcast
Woman of the Week: Novartis’ Christy Siegel
The oncology portfolio general manager for breast and women’s cancers, discusses the company’s recent “landmark” trial and how her family’s history connects her to patients.
By Taren Grom and Meagan Parrish • Aug. 15, 2023 -
PBMs could soon feel the regulatory sting
From Congress to the FTC to state legislatures, regulators are cracking the whip against PBMs.
By Karissa Waddick • Aug. 4, 2023 -
Profile
Putting purpose over profits, this pharma takes on the important issues
Afaxys is a self-described "socially conscious" contraceptive healthcare company serving an unusual demographic for pharma: the public health sector.
By Alexandra Pecci • Aug. 1, 2023 -
Threads joins the social media fray. Here’s what it means for pharma marketers.
Meta’s new platform is drawing Twitter comparisons and could hold potential for pharma marketers in patient and HCP communication.
By Karissa Waddick • July 18, 2023 -
Q&A // First 90 Days
A BMS exec’s journey around the world in 90 days
As BMS grapples with upcoming patent cliffs, Emma Charles, the new SVP of intercontinental markets, is focused on expanding its footprint.
By Karissa Waddick • July 5, 2023 -
Podcast
Woman of the Week: Gamida Cell’s Abbey Jenkins
The first-time CEO discusses the lessons she has learned since taking the role last year and how she’s pivoting the company into a commercial entity.
By Taren Grom • June 14, 2023 -
Q&A
Ranking reveals biopharma’s most innovative companies
IDEA Pharma’s 12th index finds that Pfizer and AstraZeneca reign supreme again.
By Taren Grom • June 7, 2023 -
Podcast
Woman of the Week: Marinus Pharmaceuticals’ Christy Shafer
The chief commercial officer shares how the company “beat the odds” to bring a rare disease drug to market.
By Taren Grom • June 7, 2023 -
Opinion
A key to ‘winning’ in today’s market — and other trends pharma leaders are tracking
Healthcare pros share the market drivers they believe are having the biggest impact on the industry.
By Taren Grom • June 2, 2023